PsyBio Therapeutics Appoints Pharmaceutical Veteran Bob Oliver to its Board of Directors
Mr. Oliver joins PsyBio bringing over 25 years of executive pharmaceutical experience having held various senior positions at Otsuka, Wyeth and Johnson & Johnson
News provided by
Share this article
Share this article
PsyBio or the
Company ), a biotechnology company pioneering the next generation of targeted psychoactive medications, is pleased to announce the appointment of Mr. Bob Oliver to the Company s board of directors (the
Board ), effective immediately. The Company is developing a platform technology that produces tryptamines, such as psilocybin and its intermediates, for intended therapeutic use. Mr. Oliver has extensive experience in launching pharmaceutical products into global markets offering invaluable depth to our team.